2 news items
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
UBX
14 May 24
, active-controlled study designed to evaluate the safety and efficacy of UBX1325 in comparison to aflibercept. It is expected to enroll about 50 subjects
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
UBX
23 Apr 24
upsized from 40 to 50 patients to increase the statistical power. The ASPIRE study is designed to evaluate the safety, efficacy, and long-term
- Prev
- 1
- Next